Quadrant Capital Group LLC Increases Stock Position in Astrazeneca Plc $AZN

Quadrant Capital Group LLC raised its position in Astrazeneca Plc (NYSE:AZN) by 4.9% in the 4th quarter, Holdings Channel.com reports. The fund owned 98,929 shares of the company’s stock after acquiring an additional 4,648 shares during the quarter. Astrazeneca makes up approximately 0.5% of Quadrant Capital Group LLC’s portfolio, making the stock its 25th biggest position. Quadrant Capital Group LLC’s holdings in Astrazeneca were worth $17,362,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Cibc World Market Inc. boosted its stake in Astrazeneca by 21.5% in the third quarter. Cibc World Market Inc. now owns 64,421 shares of the company’s stock valued at $4,942,000 after acquiring an additional 11,398 shares in the last quarter. TD Asset Management Inc lifted its position in Astrazeneca by 20.0% during the third quarter. TD Asset Management Inc now owns 1,089,612 shares of the company’s stock valued at $83,595,000 after purchasing an additional 181,273 shares during the period. AMG National Trust Bank raised its stake in shares of Astrazeneca by 20.4% during the 3rd quarter. AMG National Trust Bank now owns 42,983 shares of the company’s stock valued at $3,298,000 after buying an additional 7,289 shares during the last quarter. Assetmark Inc. raised its stake in shares of Astrazeneca by 6.5% during the 3rd quarter. Assetmark Inc. now owns 310,383 shares of the company’s stock valued at $23,813,000 after buying an additional 19,020 shares during the last quarter. Finally, US Bancorp DE increased its holdings in Astrazeneca by 6.6% in the third quarter. US Bancorp DE now owns 242,181 shares of the company’s stock valued at $18,581,000 after buying an additional 15,065 shares in the last quarter. 20.35% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

AZN has been the subject of a number of recent analyst reports. UBS Group reaffirmed a “buy” rating on shares of Astrazeneca in a report on Friday, April 10th. Weiss Ratings restated a “buy (b)” rating on shares of Astrazeneca in a research report on Monday. TD Cowen restated a “buy” rating on shares of Astrazeneca in a research report on Wednesday, March 18th. JPMorgan Chase & Co. reiterated a “buy” rating on shares of Astrazeneca in a report on Tuesday. Finally, Barclays reiterated a “buy” rating on shares of Astrazeneca in a report on Monday, June 1st. Twelve analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $205.33.

Astrazeneca Trading Down 1.9%

Shares of NYSE:AZN opened at $178.79 on Friday. Astrazeneca Plc has a 52 week low of $137.23 and a 52 week high of $212.71. The company’s 50 day moving average is $189.26 and its two-hundred day moving average is $185.90. The company has a current ratio of 0.91, a quick ratio of 0.71 and a debt-to-equity ratio of 0.52. The company has a market cap of $277.28 billion, a PE ratio of 26.85, a P/E/G ratio of 1.59 and a beta of 0.25.

Astrazeneca (NYSE:AZN) last announced its quarterly earnings data on Wednesday, April 29th. The company reported $2.58 EPS for the quarter, beating analysts’ consensus estimates of $2.52 by $0.06. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. The company had revenue of $15.29 billion for the quarter, compared to the consensus estimate of $14.93 billion. Equities analysts predict that Astrazeneca Plc will post 9.37 earnings per share for the current fiscal year.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.